Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update

References

• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–6
   PubMed Web of Science ®Google Scholar
• Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127–32
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–80
   PubMed Web of Science ®Google Scholar
• Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004; 103: 523–9
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9: 976–80
   PubMed Web of Science ®Google Scholar
• Bekkenk MW, Vermeer MH, Meijer CJ, et al. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 2003; 102: 4243
   PubMed Web of Science ®Google Scholar
• Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003; 35: 362–7
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–7
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–25
   PubMed Web of Science ®Google Scholar
• Druker B J. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 354: 2594–6
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–17
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–41
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532–9
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055–63
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835–44
   PubMed Web of Science ®Google Scholar
• Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995; 55: 4182–7
   PubMed Web of Science ®Google Scholar
• Huang Y, Wange R L. T cell receptor signaling: beyond complex complexes. J Biol Chem 2004; 279: 28827–30
   PubMedGoogle Scholar
• Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004; 23: 7990–8000
   PubMed Web of Science ®Google Scholar
• Groves T, Smiley P, Cooke MP, et al. Fyn can partially substitute for Lck in T lymphocyte development. Immunity 1996; 5: 417–28
   PubMed Web of Science ®Google Scholar
• Gorska MM, Stafford SJ, Cen O, et al. Unc119, a novel activator of Lck/Fyn, is essential for T cell activation. J Exp Med 2004; 199: 369–79
   PubMedGoogle Scholar
• Raab M, da Silva AJ, Findell PR, et al. Regulation of Vav-SLP-76 binding by ZAP-70 and its relevance to TCR zeta/CD3 induction of interleukin-2. Immunity 1997; 6: 155–64
   PubMed Web of Science ®Google Scholar
• Zhang W, Sloan-Lancaster J, Kitchen J, et al. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998; 92: 83–92
   PubMed Web of Science ®Google Scholar
• Wardenburg JB, Fu C, Jackman JK, et al. Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function. J Biol Chem 1996; 271: 19641–4
   PubMedGoogle Scholar
• Raab M, Cai YC, Bunnell SC, et al. p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. Proc Natl Acad Sci USA 1995; 92: 8891–5
   PubMedGoogle Scholar
• Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3: 939–51
   PubMed Web of Science ®Google Scholar
• Acuto O, Mise-Omata S, Mangino G, et al. Molecular modifiers of T cell antigen receptor triggering threshold: the mechanism of CD28 costimulatory receptor. Immunol Rev 2003; 192: 21–31
   PubMedGoogle Scholar
• Chuang E, Lee KM, Robbins MD, et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol 1999; 162: 1270–7
   PubMed Web of Science ®Google Scholar
• Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998; 282: 2263–6
   PubMed Web of Science ®Google Scholar
• Zipfel PA, Zhang W, Quiroz M, et al. Requirement for Abl kinases in T cell receptor signaling. Curr Biol 2004; 14: 1222–31
   PubMed Web of Science ®Google Scholar
• Druker B J. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21: 8541–6
   PubMed Web of Science ®Google Scholar
• Roose JP, Diehn M, Tomlinson MG, et al. T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. PLoS Biol 2003; 1: E53
   PubMedGoogle Scholar
• Schwartzberg PL, Stall AM, Hardin JD, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65: 1165–75
   PubMed Web of Science ®Google Scholar
• Tybulewicz VL, Crawford CE, Jackson PK, et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65: 1153–63
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–9
   PubMed Web of Science ®Google Scholar
• Dietz AB, Souan L, Knutson GJ, et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–9
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–9
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329–36
   PubMed Web of Science ®Google Scholar
• Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14: 2484–91
   PubMed Web of Science ®Google Scholar
• Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366–77
   PubMed Web of Science ®Google Scholar
• Blake S, Hughes TP, Mayrhofer G, et al. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127(3)330–339
   PubMedGoogle Scholar
• Chen J, Schmitt A, Chen B , et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signaling. J Cell Mol Med 2008. [ Epub ahead of print]
   Google Scholar
• Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259–64
   PubMed Web of Science ®Google Scholar
• Brauer KM, Werth D, von Schwarzenberg K, et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 2007; 67: 5489–97
   PubMed Web of Science ®Google Scholar
• Wang H, Cheng F, Cuenca A, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105: 1135–43
   PubMed Web of Science ®Google Scholar
• Bocchia M, Abruzzese E, Forconi F, et al. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 2006; 20: 142–3
   Google Scholar
• Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003; 4: 835–42
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–5
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Kroger N, Schwerdtfeger R, et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9–17
   PubMed Web of Science ®Google Scholar
• Shimoni A, Kroger N, Zander AR, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–7
   PubMed Web of Science ®Google Scholar
• Perz JB, Khorashad JS, Marin D, et al. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica 2006; 91: 1145–6
   Google Scholar
• Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–9
   PubMed Web of Science ®Google Scholar
• Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91: 663–6
   PubMed Web of Science ®Google Scholar
• Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009–15
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007; 110: 340–4
   PubMed Web of Science ®Google Scholar
• Mohty M, Blaise D, Olive D, et al. Imatinib: the narrow line between immune tolerance and activation. Trends Mol Med 2005; 11: 397–402
   PubMedGoogle Scholar
• Appel S, Balabanov S, Brummendorf TH, et al. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005; 23: 1082–8
   PubMed Web of Science ®Google Scholar
• Wolf D, Tilg H, Rumpold H, et al. The kinase inhibitor imatinib: an immunosuppressive drug?. Curr Cancer Drug Targets 2007; 7: 251–8
   Google Scholar
• Appel S, Brossart P. Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. Endocr Metab Immune Disord Drug Targets 2007; 7: 93–7
   PubMedGoogle Scholar
• Mumprecht S, Matter M, Pavelic V, et al. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 2006; 108: 3406–13
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767–811
   PubMed Web of Science ®Google Scholar
• Dittel BN, Visintin I, Merchant RM, et al. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 32–9
   Google Scholar
• Ludewig B, Odermatt B, Landmann S, et al. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 1998; 188: 1493–501
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V, Palucka A K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004; 20: 539–50
   PubMed Web of Science ®Google Scholar
• Chen M, Wang YH, Wang Y, et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006; 311: 1160–4
   PubMed Web of Science ®Google Scholar
• Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510–7
   PubMed Web of Science ®Google Scholar
• Collin MP, Munster D, Clark G, et al. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of graft-versus-host disease. Transplantation 2005; 79: 722–5
   Google Scholar
• Chan GW, Gorgun G, Miller KB, et al. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 170–6
   PubMed Web of Science ®Google Scholar
• Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586–91
   PubMed Web of Science ®Google Scholar
• Auffermann-Gretzinger S, Eger L, Schetelig J, et al. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia. Transplantation 2007; 83: 1268–72
   Google Scholar
• Chu CL, Lowell C A. The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J Immunol 2005; 175: 2880–9
   Google Scholar
• Napolitani G, Bortoletto N, Racioppi L, et al. Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol 2003; 33: 2832–41
   PubMed Web of Science ®Google Scholar
• Appel S, Boehmler AM, Grunebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538–44
   PubMed Web of Science ®Google Scholar
• Appel S, Rupf A, Weck MM, et al. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res 2005; 11: 1928–40
   PubMed Web of Science ®Google Scholar
• Taieb J, Maruyama K, Borg C, et al. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 2004; 103: 1966–7
   PubMed Web of Science ®Google Scholar
• Dewar AL, Domaschenz RM, Doherty KV, et al. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003; 17: 1713–21
   PubMed Web of Science ®Google Scholar
• Sato N, Narita M, Takahashi M, et al. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2003; 21: 67–75
   PubMedGoogle Scholar
• Kawakami Y, Inagaki N, Salek-Ardakani S, et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci USA 2006; 103: 153–8
   PubMed Web of Science ®Google Scholar
• Gagliardi MC, Finocchi A, Orlandi P, et al. Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell function. Clin Exp Immunol 2003; 133: 115–22
   Google Scholar
• Hipp MM, Hilf N, Walter S, et al. Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111(12)5610–5620
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12: 214–9
   PubMed Web of Science ®Google Scholar
• Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12: 207–13
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker B J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–53
   PubMed Web of Science ®Google Scholar
• Boissel N, Rousselot P, Raffoux E, et al. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J Leukoc Biol 2006; 79: 747–56
   Google Scholar
• Reeves PM, Bommarius B, Lebeis S, et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005; 11: 731–9
   PubMed Web of Science ®Google Scholar